Metabolomics-based profiles predictive of low bone mass in menopausal women

Takeshi Miyamoto, Akiyoshi Hirayama, Yuiko Sato, Tami Koboyashi, Eri Katsuyama, Hiroya Kanagawa, Atsuhiro Fujie, Mayu Morita, Ryuichi Watanabe, Toshimi Tando, Kana Miyamoto, Takashi Tsuji, Atsushi Funayama, Tomoyoshi Soga, Masaru Tomita, Masaya Nakamura, Morio Matsumoto

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Osteoporosis is a skeletal disorder characterized by compromised bone strength and increased risk of fracture. Low bone mass and/or pre-existing bone fragility fractures serve as diagnostic criteria in deciding when to start medication for osteoporosis. Although osteoporosis is a metabolic disorder, metabolic markers to predict reduced bone mass are unknown. Here, we show serum metabolomics profiles of women grouped as pre-menopausal with normal bone mineral density (BMD) (normal estrogen and normal BMD; NN), post-menopausal with normal BMD (low estrogen and normal BMD; LN) or post-menopausal with low BMD (low estrogen and low BMD; LL) using comprehensive metabolomics analysis. To do so, we enrolled healthy volunteer and osteoporosis patient female subjects, surveyed them with a questionnaire, measured their BMD, and then undertook a comprehensive metabolomics analysis of sera of the three groups named above. We identified 24 metabolites whose levels differed significantly between NN/LN and NN/LL groups, as well as 18 or 10 metabolites whose levels differed significantly between NN/LN and LN/LL, or LN/LL and NN/LN groups, respectively. Our data shows metabolomics changes represent useful markers to predict estrogen deficiency and/or bone loss.

Original languageEnglish
Pages (from-to)11-18
Number of pages8
JournalBone Reports
Volume9
DOIs
Publication statusPublished - 01-12-2018

Fingerprint

Metabolomics
Bone Density
Bone and Bones
Osteoporosis
Estrogens
Bone Fractures
Serum
Healthy Volunteers

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Orthopedics and Sports Medicine

Cite this

Miyamoto, T., Hirayama, A., Sato, Y., Koboyashi, T., Katsuyama, E., Kanagawa, H., ... Matsumoto, M. (2018). Metabolomics-based profiles predictive of low bone mass in menopausal women. Bone Reports, 9, 11-18. https://doi.org/10.1016/j.bonr.2018.06.004
Miyamoto, Takeshi ; Hirayama, Akiyoshi ; Sato, Yuiko ; Koboyashi, Tami ; Katsuyama, Eri ; Kanagawa, Hiroya ; Fujie, Atsuhiro ; Morita, Mayu ; Watanabe, Ryuichi ; Tando, Toshimi ; Miyamoto, Kana ; Tsuji, Takashi ; Funayama, Atsushi ; Soga, Tomoyoshi ; Tomita, Masaru ; Nakamura, Masaya ; Matsumoto, Morio. / Metabolomics-based profiles predictive of low bone mass in menopausal women. In: Bone Reports. 2018 ; Vol. 9. pp. 11-18.
@article{7c698043391646f2898629e2cbb8f8f3,
title = "Metabolomics-based profiles predictive of low bone mass in menopausal women",
abstract = "Osteoporosis is a skeletal disorder characterized by compromised bone strength and increased risk of fracture. Low bone mass and/or pre-existing bone fragility fractures serve as diagnostic criteria in deciding when to start medication for osteoporosis. Although osteoporosis is a metabolic disorder, metabolic markers to predict reduced bone mass are unknown. Here, we show serum metabolomics profiles of women grouped as pre-menopausal with normal bone mineral density (BMD) (normal estrogen and normal BMD; NN), post-menopausal with normal BMD (low estrogen and normal BMD; LN) or post-menopausal with low BMD (low estrogen and low BMD; LL) using comprehensive metabolomics analysis. To do so, we enrolled healthy volunteer and osteoporosis patient female subjects, surveyed them with a questionnaire, measured their BMD, and then undertook a comprehensive metabolomics analysis of sera of the three groups named above. We identified 24 metabolites whose levels differed significantly between NN/LN and NN/LL groups, as well as 18 or 10 metabolites whose levels differed significantly between NN/LN and LN/LL, or LN/LL and NN/LN groups, respectively. Our data shows metabolomics changes represent useful markers to predict estrogen deficiency and/or bone loss.",
author = "Takeshi Miyamoto and Akiyoshi Hirayama and Yuiko Sato and Tami Koboyashi and Eri Katsuyama and Hiroya Kanagawa and Atsuhiro Fujie and Mayu Morita and Ryuichi Watanabe and Toshimi Tando and Kana Miyamoto and Takashi Tsuji and Atsushi Funayama and Tomoyoshi Soga and Masaru Tomita and Masaya Nakamura and Morio Matsumoto",
year = "2018",
month = "12",
day = "1",
doi = "10.1016/j.bonr.2018.06.004",
language = "English",
volume = "9",
pages = "11--18",
journal = "Bone Reports",
issn = "2352-1872",
publisher = "Elsevier Inc.",

}

Miyamoto, T, Hirayama, A, Sato, Y, Koboyashi, T, Katsuyama, E, Kanagawa, H, Fujie, A, Morita, M, Watanabe, R, Tando, T, Miyamoto, K, Tsuji, T, Funayama, A, Soga, T, Tomita, M, Nakamura, M & Matsumoto, M 2018, 'Metabolomics-based profiles predictive of low bone mass in menopausal women', Bone Reports, vol. 9, pp. 11-18. https://doi.org/10.1016/j.bonr.2018.06.004

Metabolomics-based profiles predictive of low bone mass in menopausal women. / Miyamoto, Takeshi; Hirayama, Akiyoshi; Sato, Yuiko; Koboyashi, Tami; Katsuyama, Eri; Kanagawa, Hiroya; Fujie, Atsuhiro; Morita, Mayu; Watanabe, Ryuichi; Tando, Toshimi; Miyamoto, Kana; Tsuji, Takashi; Funayama, Atsushi; Soga, Tomoyoshi; Tomita, Masaru; Nakamura, Masaya; Matsumoto, Morio.

In: Bone Reports, Vol. 9, 01.12.2018, p. 11-18.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Metabolomics-based profiles predictive of low bone mass in menopausal women

AU - Miyamoto, Takeshi

AU - Hirayama, Akiyoshi

AU - Sato, Yuiko

AU - Koboyashi, Tami

AU - Katsuyama, Eri

AU - Kanagawa, Hiroya

AU - Fujie, Atsuhiro

AU - Morita, Mayu

AU - Watanabe, Ryuichi

AU - Tando, Toshimi

AU - Miyamoto, Kana

AU - Tsuji, Takashi

AU - Funayama, Atsushi

AU - Soga, Tomoyoshi

AU - Tomita, Masaru

AU - Nakamura, Masaya

AU - Matsumoto, Morio

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Osteoporosis is a skeletal disorder characterized by compromised bone strength and increased risk of fracture. Low bone mass and/or pre-existing bone fragility fractures serve as diagnostic criteria in deciding when to start medication for osteoporosis. Although osteoporosis is a metabolic disorder, metabolic markers to predict reduced bone mass are unknown. Here, we show serum metabolomics profiles of women grouped as pre-menopausal with normal bone mineral density (BMD) (normal estrogen and normal BMD; NN), post-menopausal with normal BMD (low estrogen and normal BMD; LN) or post-menopausal with low BMD (low estrogen and low BMD; LL) using comprehensive metabolomics analysis. To do so, we enrolled healthy volunteer and osteoporosis patient female subjects, surveyed them with a questionnaire, measured their BMD, and then undertook a comprehensive metabolomics analysis of sera of the three groups named above. We identified 24 metabolites whose levels differed significantly between NN/LN and NN/LL groups, as well as 18 or 10 metabolites whose levels differed significantly between NN/LN and LN/LL, or LN/LL and NN/LN groups, respectively. Our data shows metabolomics changes represent useful markers to predict estrogen deficiency and/or bone loss.

AB - Osteoporosis is a skeletal disorder characterized by compromised bone strength and increased risk of fracture. Low bone mass and/or pre-existing bone fragility fractures serve as diagnostic criteria in deciding when to start medication for osteoporosis. Although osteoporosis is a metabolic disorder, metabolic markers to predict reduced bone mass are unknown. Here, we show serum metabolomics profiles of women grouped as pre-menopausal with normal bone mineral density (BMD) (normal estrogen and normal BMD; NN), post-menopausal with normal BMD (low estrogen and normal BMD; LN) or post-menopausal with low BMD (low estrogen and low BMD; LL) using comprehensive metabolomics analysis. To do so, we enrolled healthy volunteer and osteoporosis patient female subjects, surveyed them with a questionnaire, measured their BMD, and then undertook a comprehensive metabolomics analysis of sera of the three groups named above. We identified 24 metabolites whose levels differed significantly between NN/LN and NN/LL groups, as well as 18 or 10 metabolites whose levels differed significantly between NN/LN and LN/LL, or LN/LL and NN/LN groups, respectively. Our data shows metabolomics changes represent useful markers to predict estrogen deficiency and/or bone loss.

UR - http://www.scopus.com/inward/record.url?scp=85048828187&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048828187&partnerID=8YFLogxK

U2 - 10.1016/j.bonr.2018.06.004

DO - 10.1016/j.bonr.2018.06.004

M3 - Article

AN - SCOPUS:85048828187

VL - 9

SP - 11

EP - 18

JO - Bone Reports

JF - Bone Reports

SN - 2352-1872

ER -

Miyamoto T, Hirayama A, Sato Y, Koboyashi T, Katsuyama E, Kanagawa H et al. Metabolomics-based profiles predictive of low bone mass in menopausal women. Bone Reports. 2018 Dec 1;9:11-18. https://doi.org/10.1016/j.bonr.2018.06.004